Key facts
- This page summarizes Margaret Dalesandro's Form 4 filing for Ambrx Biopharma, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Mar 2024, 17:36.
Margaret Dalesandro - 07 Mar 2024 Form 4 Insider Report for Ambrx Biopharma, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 07 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2024, 17:36:33 UTC
- Prior SEC filing
- 04 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sonja Nelson, Attorney-in-Fact for Margaret Dalesandro
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Margaret Dalesandro filed Form 4 for Ambrx Biopharma, Inc. on 07 Mar 2024.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMAM
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -17,857
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,857
- Exercise price
- Footnotes
- F1, F2, F3, F4
AMAM
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -10,119
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,119
- Exercise price
- Footnotes
- F1, F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Margaret Dalesandro is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
Footnote F2
Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").
Footnote F3
The RSUs vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date.
Footnote F4
Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
Footnote F5
The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant of September 1, 2023, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date.